Clinical Trials
26 trialsNCT05267626 2026-05-18
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT02830724 2026-04-06
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT07063875 2025-07-14
SILVER
St Vincent's Hospital, Sydney
Phase 1/2 Recruiting
NCT01740557 2024-10-08
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT06152367 2023-11-30
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
University of Chile
Phase 1/2 Completed
NCT00945269 2022-11-15
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT02111850 2022-03-29
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02379195 2020-01-22
Peginterferon and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT01218867 2019-12-10
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00062036 2017-07-02
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00871481 2017-04-19
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01758458 2017-04-19
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT00553306 2017-02-15
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01273181 2015-10-28
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00937625 2015-08-18
T-cell Based Immunotherapy for of Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT00004025 2014-01-06
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00019214 2013-06-20
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00058279 2013-06-20
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00003229 2013-03-25
Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal
Duke University
Phase 1/2 Completed
NCT00052377 2013-01-16
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00924001 2012-10-25
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01409187 2012-01-26
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00002786 2010-05-10
Biological Therapy in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00197912 2010-04-26
Dendritic Cell Based Therapy of Malignant Melanoma
Herlev Hospital
Phase 1/2 Completed